Introduction
The treatment of cancer with chemotherapy is undergoing an "intravenous-to-oral" switch trend which has led to an increasing availability of oral formulations with anticancer drugs (oncolytics). The advantage is that oral formulations bypass the need for hospitalization to administer the drug, making it possible to treat cancer in a more home-based setting, which many cancer patients actually prefer [1] [2] [3] . Another advantage is that oral oncolytics make possible continuous chemotherapy schedules. An important group of oncolytics which are dosed continuously are the tyrosine kinase inhibitors which exert their antineoplastic action by interfering with tumor-specific molecular pathways, referred to as targeted chemotherapy [4] . A prerequisite for orally administered drugs, in particular for oncolytics, is a complete and consistent absorption process because these agents usually have a steep dose-response curve and a narrow therapeutic index [5] . In order to reach the systemic circulation the drug must dissolve from its pharmaceutical dosage form (capsule or tablet) in the gastro-intestinal fluid. The problem is that many drugs have a poor solubility in water which can lead to incomplete and unpredictable absorption and consequently in a negative treatment outcome such as under-or overdosing [4, 6, 7] . Moreover, absorption of low-solubility drugs can be significantly affected by food or drinks, e.g. by modifying the pH environment, which is obviously rather uncontrolled [8, 9] . Therapeutic drug monitoring is one way to adjust the dose when inadequate in-vivo drug concentrations are achieved [5, 10, 11] . However, drugs with dissolution-limited absorption often result in high day-to-day variability in in-vivo drug concentrations (i.e. intra-patient variability) which is difficult to adjust to with therapeutic drug monitoring [11, 12] . Besides, therapeutic drug monitoring adjusts doses retrospectively, requires extra healthcare infrastructure such as patient sampling and bioanalysis [10] and, what is more, it does not solve the problem of dissolution-limited absorption.
The core of the problem of dissolution-limited absorption might be addressed by optimization of the pharmaceutical formulation. Currently there are different formulation strategies at hand to enhance drug dissolution and a very promising one is the solid dispersion approach. There are currently 27 solid dispersion formulations commercially available (including 3 orally dosed oncolytics), with examples of achieving even a 30 times increased drug dissolution (i.e. vemurafenib solid dispersion), highlighting the feasibility and success of this formulation method [13, 14] .
This review discusses the basics of drug dissolution, focuses on the solid dispersion formulation technique and addresses which oral oncolytic formulations have dissolutionlimited absorption pharmacokinetics and are potential candidates for a solid dispersion formulation.
Conventional pharmaceutical formulations and the basics of drug dissolution
As can be seen in Fig. 1 , most of the commercially available oral oncolytics are physical mixture formulations (67%), followed by prodrugs (18%), lipid formulations (10%), solid dispersions (4%) and co-solvents (1%).
Physical mixtures contain mechanically mixed crystalline drug powder, filling powder (e.g. cellulose, lactose or starch), disintegrant (e.g. croscarmellose), glidant (e.g. silicon dioxide) and lubricant (e.g. magnesium stearate). To obtain the final dosage form, physical mixtures are pressed into tablets or filled in capsules. Physical mixtures are standard oral drug formulations because development of such a formulation is simple and inexpensive [15] . An example of a physical mixture formulation is anastrozole (Arimidex ® ). A schematic representation of what happens to a capsule or a tablet containing a physical powder mixture after oral intake is shown in Fig. 2 . The shell of the capsule dissolves in water and the powder is then wetted. In the case of tablets, penetrating water breaks down the tablet into large particles (agglomerates) and then to finer particles [16, 17] . The next step is solvation and is facilitated by water molecules surrounding the drug molecule. Solvated drug molecules then diffuse into the bulk environment volume, resulting in dissolution. Only dissolved drug molecules can pass epithelial cells in the gastro-intestinal tract for absorption [18] .
A prodrug formulation contains a biologically inactive compound which is converted in-vivo to the pharmacologically active drug [19] , a strategy which can be used if the active drug has poor oral absorption either due to poor dissolution or due to extensive metabolism. Prodrug powders are processed into a capsule or a tablet in the same way as physical mixtures. An example of a prodrug formulation in capecitabine (Xeloda ® ).
In lipid-based formulations the drug is dissolved or dispersed in lipid excipients (i.e. mono, di, or triglyceride). Endogenous lipid-digesting enzymes and bile-salts transform the lipid formulation into emulsification droplets, resulting in drug dissolution. Surfactants (i.e. polyglyceride fatty esters, polyethylene glycol) can be added to speed up the emulsification process and to enhance drug dissolution, a feature which is used in a self-emulsifying drug delivery system (SEDDS). SEDDS is an isotropic mixture of lipids, surfactants and cosolvents and when agitated in water it readily forms an emulsion with droplets < 300 nm.
Lipid-based formulations can be liquid, solid or semi-solid. A disadvantage is that many lipidbased formulations require careful handling and storage because they can be physically and/or chemically unstable. Lipid-based formulations (in particular SEDDS) may contain high amounts of surfactants (usually 30 -60% of the formulation) and this can cause gastrointestinal toxicity [20] [21] [22] [23] . An example of a lipid-based formulation is tretinoin (Vesanoid   ®   ) and an example of a SEDDS is olaparib (Lynparza ® ).
A co-solvent formulation contains an organic solvent to increase drug dissolution in water (i.e. ethanol or propylene glycol). The disadvantage is that organic co-solvents can evaporate through capsule shells (even if the capsule is sealed) and this may lead to drug precipitation in the formulation. Besides organic solvents can be toxic [15, 22] . An example of a co-solvent formulation is vinorelbine (Navelbine ® ).
Capsules or tablets may also have a coating: an extra layer on the exterior of the capsule or tablet. Coatings can be used to protect the dosage form against light, moisture and/or mechanical stress, to make the dosage form look more attractive/recognizable or for controlled disintegration. Regarding the latter, an example is an enteric-resistant coating which has a pH-dependent solubility (no solubility in stomach pH, high solubility in the intestine), hence the dosage form does not degrade in the stomach. This can be applied to drugs with poor stability in acidic pH such as in the stomach [24] .
Factors affecting drug dissolution
The process of drug dissolution is influenced by parameters that are described in the NoyesWhitney equation [25, 26] :
Where dW/dt is drug dissolution rate during a certain period of time (e.g. mg/min), D the diffusion coefficient (e.g. cm 2 /min), A the surface area of the drug (e.g. cm 2 ), C s the saturation solubility of the drug (e.g. mg/L), C the concentration of the drug (e.g. mg/L) and h the thickness of the diffusion layer (e.g. cm). A is related to powder particle size (smaller particles result in a larger surface area), wettability of the powder and by surfactants in gastro-intestinal fluids and bile. D describes the diffusivity of a drug and is influenced by molecule size and viscosity of gastro-intestinal fluids. Parameter h is determined by the viscosity and surfactant concentration in gastro-intestinal fluids as well as by contractile patterns in the gastro-intestinal tract [4, 18] . C s is governed by intrinsic drug molecule properties such as molecular mass, Log P, the number of hydrogen donors/acceptors and the pK a [18, 27] .
Biopharmaceutics Classification System (BCS) and Biopharmaceutics Drug Disposition Classification System (BDDCS)
There are two different systems that use biopharmaceutical properties of a drug molecule to predict drug absorption [28] . The biopharmaceutical classification system (BCS) classifies drugs by solubility in water and permeability across human epithelial cells. A drug can fall in either of the four classes: high solubility-high permeability (class I), low solubility-high permeability (class II), high solubility-low permeability (class III) and low solubility-low permeability (class IV) [28] [29] [30] . A drug is considered highly permeable if >90% of the dose is absorbed by epithelial cells and soluble when the highest dose strength dissolves in 250 mL water over pH range 1.2 -7.4 [31] .
The other system, BDDCS, describes the biopharmaceutics of a drug by solubility in water and in-vivo disposition. Criteria for solubility in water are the same as used with BCS. The disposition of a drug is influenced by enzymatic, -and transporter processes, consequently BDDCS describes whether a drug undergoes first-pass metabolism and whether it is a substrate to drug efflux transporters such as ATP-binding cassette transporters (ABC) [4, 32, 33] . Drugs with high permeability are readily absorbed, facilitating access to metabolic enzymes and this then results in high metabolism. This makes BDDCS more representative to describe the absorption pharmacokinetics of a drug [28, 30] . BDDCS classes are: high solubility-high metabolism (class I), low solubility-high metabolism (class II), high solubilitylow metabolism (class III) and low solubility-low metabolism (class IV).
Currently, 90% of orally administered drugs in clinical development are categorized as BCS/BDDCS II or IV [30] and 40% fails because of insufficient biopharmaceutical properties such as poor drug dissolution [18] . This underlines that the pharmaceutical formulation is a crucial part in drug development.
Solid dispersions
A solid dispersion consists of a drug that is dispersed in a hydrophilic excipient which can be a small molecule such as urea or sugar [34] or a biologically inactive polymer such as cellulose derivatives, polyethyleneglycols, polyvinylpyrrolidones, polyvinylalcohols, polyacrylates and sugar polyols [35] [36] [37] . A solid dispersion is not just a physical powder mixture of drug and excipient. Instead, a solid dispersion consists of powder particles in 8 which drug and excipient are integrated and therefore appears as a one-phase powder, with considerably smaller powder particles than what can be achieved with mechanical milling processes [6, 7, 33, 35, [38] [39] [40] [41] [42] . The very fine dispersion of drug and excipient, decreased particle size and the hydrophilic character of the excipient result in enhanced drug dissolution [43] .
Types of solid dispersions
An important feature of a solid dispersion is the physical state of the powder: it can be crystalline or amorphous [37, 40, 44] . The difference between crystalline powders and amorphous powders is illustrated in Table 1 . Crystalline powders contain molecules that are arranged in a highly ordered way. The lattice structure in a crystal results in rigid and physically stable powder particles. Crystalline particles are relatively large and coarse (usually 50 -1000 µm [45] ). Water must first break down the lattice energy holding the crystal together in order to allow solvation and then drug dissolution. Amorphous powders are irregularly organized molecules with considerably smaller particle size, usually < 50 µm.
Consequently, the particle surface area of amorphous powders is larger than that of crystalline powders. The absence of lattice energy bonds and the larger particle surface area of amorphous powders result in higher drug dissolution [46] . The disadvantage of amorphous powders, however, is that the molecular structure is physically unstable and over time crystal bonding between molecules develops, affecting the dissolution [43, 46] . This makes it difficult to retain an amorphous powder. Table 1 also compares drug dissolution from a crystalline powder and an amorphous powder: the saturation solubility from an amorphous powder is higher than from a crystalline powder and is then "super-saturated". The highest concentration in this phase is known as S max . The super-saturated state is temporarily because the drug precipitates back to the saturation concentration equal to that of the crystal form, S equilibrium . The moment that precipitation starts, is the precipitation onset time, T precipitation .
The temporarily super-saturated drug solution creates a time window for enhanced in-vivo absorption. The role of the hydrophilic excipient in a solid dispersion is to support supersaturation and to inhibit precipitation [14, 40, 43] .
The type of the solid dispersion is determined by the physical state of drug and excipient (crystalline or amorphous). There are crystalline solid dispersions, amorphous solid dispersions and crystalline-amorphous solid dispersions and their characteristics are shown in Table 2 .
First, among crystalline solid dispersions are the eutectic mixtures which were actually the first known solid dispersions [40] . Eutectic solid dispersions are made by heating up a powder mixture at weight proportions at which drug and excipient melt simultaneously, followed by a cooling-down phase [34, 40] . Each compound has its own specific melting temperature but when used in a particular weight proportion the mixture can melt simultaneously [40] and the temperature at which this occurs is called the eutectic temperature [34] . Because the eutectic temperature is lower than the melting temperature of the individual compounds of the mixture, the production temperature can be reduced which is particularly advantageous for thermally unstable compounds. The advantage of an eutectic mixture is that drug and excipient are more homogenously mixed than in physical mixtures and this results in higher drug dissolution [37, 40] .
Another type of crystalline solid dispersions are solid solutions [34] . In solid solutions a crystalline drug is "dissolved" in a crystalline excipient which results in a single-phase powder because the lattice of the crystal consists of excipient molecules and of drug molecules. Solid solutions have smaller particles than pure crystalline drug compounds and are more homogenous than physical mixtures. This contributes to higher dissolution and absorption [40] . For example, griseofulvin-polyethylene glycol 4000 solid solution resulted in a ~2 times higher in-vivo exposure compared to crystalline griseofulvin [40] .
In an amorphous solid dispersion (i.e. glass solution) the drug "dissolves" in an amorphous excipient resulting in a one-phase amorphous powder [34, 40, 47] . The amorphous state of the powder, homogeneously mixed at molecular level, the hydrophilic character of the excipient and the large surface area result in high dissolution and absorption enhancement [40] . For example, the antiviral drug telaprevir (Incivo   ®   ) is an amorphous solid dispersion with ~32 times increased dissolution and ~10 increased bioavailability [48] . The disadvantage of amorphous solid dispersions is that they can be unstable because amorphous materials can revert to crystalline forms [34] . Therefore, amorphous solid dispersions require more careful handling and storage than crystalline solid dispersions [47] .
In a glass suspension an amorphous drug is not entirely dissolved in an amorphous excipient [40, 47] . Instead the drug is dispersed as amorphous clusters or is partially amorphouspartially crystalline [40] . Glass suspensions may occur when the amount of drug in the solid dispersion is relatively large (usually at ≥ 35%). Drug recrystallization is more likely to occur during storage and this makes glass suspensions less stable than glass solutions [47] .
In amorphous precipitates the drug precipitates out as an amorphous form and is dispersed in a crystalline excipient [40, 44] . The amorphous form of the drug and the hydrophilic character of the excipient contribute towards dissolution enhancement. For example, an amorphous dispersion of ritonavir in crystalline polyethyleneglycol 8000 resulted in a 3.5 -5
times increased dissolution and a 11 -22 times improved absorption compared to a crystalline physical mixture of ritonavir-polyethylene glycol 8000 [49, 50] .
Production methods
There are four production methods for solid dispersions: solvent-removing, melting, precipitation and electro-spinning [34, 35, 37, 41, 44, [51] [52] [53] . In the solvent-removal method, drug and excipient are dissolved in an organic solvent and the solution is then evaporated or sublimated. A commonly used evaporation apparatus is a spray dryer and works by transforming the solution into droplets which are dried with a gas (i.e. nitrogen or air) [52] . A common sublimation apparatus is a freeze dryer which freezes the solution and then induces solvent removal by reducing the air pressure [47] .
In the melting method drug and excipient are mixed and then heated until they melt. The melt mixture is then rapidly cooled and this ensures that drug and excipient stay molecularly mixed. The result is a solid mass which is then pulverized to obtain particles of a desired size [37, 44] . A commonly used apparatus is a hot melt extruder [54] .
In the precipitation process drug and excipient are dissolved in a solvent and then an antisolvent is added to induce precipitation. This results in a precipitate which is further dried to remove residual solvents and finally a dry powder is obtained [13] .
In electro-spinning a solution of drug and excipient is dried with electrical energy. The solution is placed in a syringe with a metal tip and pressed out with a pump. The application of high voltage between the metal tip of the syringe and metallic collecting material ejects elongated droplets from the syringe which then evaporate and the resulting product is a solid fiber [55] .
Examples of commercialized solid dispersion formulations
In the field of oncology there are currently three commercialized formulations that contain a Vemurafenib formulation was initially a physical mixture of crystalline vemurafenib in a capsule. However, the physical mixture resulted in poor bioavailability and a formulation switch to the solid dispersion technique was performed during clinical evaluation [13] . 
Biopharmaceutics and absorption pharmacokinetics of oral oncolytics
The absorption pharmacokinetics of commercially available oral oncolytics are shown in Table 3 . Dissolution-limited absorption is defined by the BCS/BDDCS status of the drug, incomplete oral bioavailability and high variability in concentrations/exposure in blood (whole blood, plasma or serum) by criteria:
1. The drug is classified as BCS/BDDCS II or IV;
2. Oral bioavailability < 85% [28] ;
3. Intra-patient variability in exposure ≥ 30% [12] .
In the case of unknown bioavailability and/or unknown intra-patient variability, a lack of a linear relationship between dose and concentration/exposure in blood and inter-patient variability ≥ 70% are criteria for dissolution-limited absorption. The cut-off value for interpatient variability is based on the fact that the upper limit of the 95% confidence interval of BCS/BDDCS I/III drugs studied in this review (Table 3) 
Conclusions
A crucial characteristic for complete and predictable absorption of an orally administered oncolytic is that the drug dissolves in gastro-intestinal fluids. The problem is that many orally administered oncolytics are poorly soluble in water. In half of the currently licensed arsenal of oral oncolytics poor drug dissolution is likely to play a major role in poor absorption pharmacokinetics such as incomplete bioavailability, high intra-patient variability in blood concentrations and lack of linear relationship between dose and blood concentrations.
Dissolution-limited absorption might be resolved with the solid dispersion technology because this formulation method can induce super-saturated drug dissolution and with that enhanced absorption. There are three licensed oral oncolytics with a solid dispersion formulation: vemurafenib, regorafenib and everolimus and they result in a significantly increased dissolution and enhanced absorption relative to their corresponding crystalline physical mixture formulations. We believe that the solid dispersion can be feasible and successful for improving dissolution-limited absorption of poorly soluble drugs and encourage the application of this formulation method in the pharmaceutical development of oral oncolytics. Tables   Table 1 Pharmaceutical features of a crystalline powder drug particle and an amorphous drug powder particle
Feature Crystalline Amorphous
Schematic structure of one powder particle
Molecule orientation Regular Irregular

Particle size Large Small
Particle surface area Small Large
Stability physical structure
Strong Weak
Dissolution
Reprinted from Moes et al [58] with permission from Elsevier. Precipitation inhibitor is the hydrophilic excipient of a solid dispersion which supports super-saturation and increases Tpreciptitation.
Smax: highest apparent solubility Tpreci pitation: time at which drug starts to precipitate after having reached its highest apparent solubility Sequilibrium: intrinsic solubility of the drug Reprinted from Shah et al [13] with permission from
Elsevier.
